Daisuke Kotani, GI Medical Oncologist, Chief Physician at the Department of Gastrointestinal Oncology at the National Cancer Center Hospital East, Japan, shared a post on X:
“ASCO-GI 2026, LBA285
HERIZON-GEA-01: Ph3 1L HER2+ GEA Zanidatamab + Chemo ± Tislelizumab vs Trastuzumab + Chemo
- PFS: Significant improvement in both Zani arms
- OS: Significant improvement in Zani + Chemo + Tisle arm (Zani + Chemo arm: not significant at 1st IA)
Zani + Chemo + Tisle is a potential new SOC for 1L HER2+ GEA. Longer follow-up warranted to confirm OS benefit of Zani over Tras.
According to the Jazz Pharma press release: While ORR appears similar, Zani arm demonstrated a longer DoR”
More posts featuring Daisuke Kotani.
